title: Recognition and management of IgA nephropathy.
abstract: IgA (immunoglobulin A) nephropathy is the most common form of primary glomerulonephritis worldwide. It generally has a good prognosis, with 15-year rates of kidney survival from the apparent onset of disease usually well in excess of 70%. Progression, when it occurs, is usually a slow, indolent process, and spontaneous remission of disease activity occurs in 7% of patients. It is possible to predict, from the initial presenting features and laboratory findings, renal biopsy and clinical course during follow-up, which patients are likely to have progressive renal disease. Identification of the factors likely to be associated with progression is of importance in helping to establish which patients will benefit from specific therapeutic intervention. For all patients, attention should be directed toward general health issues in an endeavour to reverse factors that are likely to have an adverse impact on renal function. This should include early detection and tight control of hypertension (present in 50% of all patients with IgA nephropathy during the course of their disease), along with utilisation of antihypertensive agents that have specific renoprotective effects, namely ACE inhibitors or calcium antagonists. Such therapy should also be considered in normotensive patients with heavy proteinuria, as a reduction of proteinuria is often achieved by this means. Other aims should include maintenance of desirable bodyweight, correction of hyperlipidaemia, cessation of smoking, participation in an active exercise programme, avoidance of exposure to nephrotoxins and maintenance of a high fluid intake. A low protein/low phosphate diet together with phosphate binder therapy should be commenced early in the course of renal impairment. Corticosteroid and/or cytotoxic drug therapy should be considered in the small percentage of patients with heavy proteinuria or a rapid decline in renal function. Such therapeutic endeavours are likely to delay the onset of renal failure in patients with progressive IgA nephropathy.
authors.affiliation: Department of Renal Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
authors.forename: L S
authors.initials: LS
authors.lastname: Ibels
authors.forename: A Z
authors.initials: AZ
authors.lastname: Gyory
authors.forename: R J
authors.initials: RJ
authors.lastname: Caterson
authors.forename: C A
authors.initials: CA
authors.lastname: Pollock
authors.forename: J F
authors.initials: JF
authors.lastname: Mahony
authors.forename: D A
authors.initials: DA
authors.lastname: Waugh
authors.forename: S
authors.initials: S
authors.lastname: Coulshed
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents